While these data suggest that CD38 is an attractive therapeutic target in ENKTL, most of the research on daratumumab has been in multiple myeloma and ENKTL-specific mechanisms of action and resistance will have to be investigated. The gene discussed is CD38; the disease is AL amyloidosis.